Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ReVance Therapeutics Inc.

This article was originally published in Start Up

Executive Summary

After spending its first three years quietly amassing preclinical and clinical data on its pipeline for aesthetic and therapeutic dermatology, Essentia Biosystems is ready to make some noise. It has unveiled a new name, ReVance Therapeutics Inc., will soon announce some key hires, and is preparing to enter the clinic with its lead candidate, a topical, "wipe-on" form of botulinum toxin delivered with the company's proprietary technology for transporting large molecule drugs through the skin.

Related Content


Related Companies

Related Deals




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts